1 | F 55 y | Squamous cell carcinoma of | nivolumab | October 2015 | October 2015 | RA | resolution with NSAIDS | anti-CCP: 671 U/ml |
| | the vagina | | | | | | RF: 18 UI/ml |
2 | F 66 y | Endometrial adenocarcinoma | pembrolizumab | March 2016 | April 2016 | RA | resolution with corticosteroids | anti-CCP: 233 U/ml |
| | | | | | | prednisone 10 mg/day | RF:180 UI/ml |
3 | M 59 y | Lung adenocarcinoma | nivolumab | May 2016 | July 2016 | RA | resolution with prednisone 10 mg/d | anti-CCP: 61 U/ml |
| | | | | | | tapered to 5 mg/d 1 months later | RF: 47 UI/ml |
4 | F 56 y | Metastatic melanoma | pembrolizumab | August 2015 | September 2015 | RA | resolution with hydroxychloroquine | anti-CCP: 22UI/ml |
| | | | | | | 400mg/day and NSAIDS | |
5 | M 80 y | Metastatic melanoma | nivolumab | April 2016 | April 2016 | RA | Resolution with prednisone 15mg/day (tapered) | anti-CCP:42 UI/ml |
| | | | | | | and hydroxychloroquine 200mg/day | |
6 | M 68 y | Lung adenocarcinoma | nivolumab | June 2015 | July 2015 | RA | Resolution after stopping nivolumab and after | anti-CCP >300U/ml |
| | | | | | | 1 month of methotrexate 10 mg/w (maintained 3 months) | RF: 246 UI/ml |